Financial Performance - The company's operating revenue for Q3 2022 was ¥466,544,863.81, representing a decrease of 6.31% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥105,129,320.08, down 34.57% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥103,095,223.20, a decrease of 24.44% compared to the same period last year[7]. - The basic earnings per share for Q3 2022 was ¥0.09, reflecting a decline of 35.71% year-on-year[10]. - Total operating revenue for the first three quarters of 2022 was ¥1,108,395,348.19, a decrease of 17.1% compared to ¥1,338,392,261.25 in the same period of 2021[32]. - Net profit for the first three quarters of 2022 was ¥204,573,959.84, a decline of 52.0% compared to ¥426,067,383.40 in the same period of 2021[36]. - Operating profit for the first three quarters of 2022 was ¥250,258,672.09, down 44.9% from ¥454,162,708.71 in the previous year[36]. - Total comprehensive income attributable to the parent company was CNY 210,277,260.15, a decrease from CNY 418,898,934.30 in the same period last year, representing a decline of approximately 49.9%[39]. - Basic and diluted earnings per share were both CNY 0.19, down from CNY 0.37 year-over-year, indicating a decrease of about 48.6%[39]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,446,660,040.53, a decrease of 2.38% from the end of the previous year[10]. - The equity attributable to shareholders at the end of the reporting period was ¥5,117,706,899.87, down 2.93% from the previous year[10]. - The total liabilities as of the reporting date were ¥1,046,386,256.26, slightly up from ¥1,043,692,738.64 in the previous year[29]. - The total assets as of the reporting date were ¥6,446,660,040.53, down from ¥6,603,925,651.78 in the previous year[29]. - The company's long-term equity investments decreased marginally to CNY 267.09 million from CNY 268.30 million, a reduction of approximately 0.5%[28]. - The total non-current assets decreased to CNY 3.75 billion from CNY 3.84 billion, indicating a decline of approximately 2.6%[28]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥210,769,176.09, showing a decrease of 18.23% compared to the same period last year[10]. - Net cash flow from operating activities was CNY 210,769,176.09, compared to CNY 257,770,973.41 in the previous year, reflecting a decline of approximately 18.2%[43]. - Cash inflow from operating activities totaled CNY 1,073,033,993.90, down from CNY 1,194,933,674.77, a decrease of about 10.1%[43]. - Cash outflow from operating activities was CNY 862,264,817.81, compared to CNY 937,162,701.36 in the previous year, showing a reduction of approximately 8.0%[43]. - Cash and cash equivalents at the end of the period were CNY 1,063,389,917.23, down from CNY 1,440,193,503.87, indicating a decrease of about 26.1%[45]. - The net cash flow from financing activities was negative at CNY -384,361,603.46, worsening from CNY -118,868,998.30 in the same period last year[45]. Shareholder Information - The company had a total of 74,093 common shareholders at the end of the reporting period[19]. - The company repurchased a total of 27,592,600 shares, which is 2.46% of the total share capital, as part of its stock buyback program[24]. Expenses - Research and development expenses for the first three quarters of 2022 were ¥88,520,367.44, a decrease of 8.5% compared to ¥96,347,351.37 in the same period of 2021[32]. - Sales expenses for the first three quarters of 2022 were ¥193,091,936.40, down 20.9% from ¥243,820,615.42 in the previous year[32]. Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.06%, a decrease of 1.03 percentage points year-on-year[10]. - The company reported a decrease in government subsidies, which contributed to the decline in net profit[15]. - The company's cash and cash equivalents decreased to CNY 1.19 billion from CNY 1.33 billion, representing a decline of approximately 10.5% year-over-year[25]. - The total current assets as of September 30, 2022, were CNY 2.69 billion, down from CNY 2.76 billion, indicating a decrease of about 2.6%[25]. - Accounts receivable increased to CNY 790.96 million from CNY 729.09 million, showing a growth of approximately 8.5% year-over-year[25]. - Inventory levels decreased slightly to CNY 301.61 million from CNY 317.65 million, reflecting a decline of about 5.0%[25]. - The company reported a significant increase in other receivables, rising to CNY 54.55 million from CNY 37.83 million, which is an increase of about 44.2%[25]. - Deferred income tax liabilities were ¥10,198,038.39, a slight decrease from ¥10,482,135.25 in the previous year[29]. - The company paid CNY 123,714,325.23 in dividends and interest, slightly down from CNY 131,430,921.43 year-over-year[43].
生物股份(600201) - 2022 Q3 - 季度财报